We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
IONTAS Announces New Antibody Optimisation Agreement with Teva Pharmaceuticals
Product News

IONTAS Announces New Antibody Optimisation Agreement with Teva Pharmaceuticals

IONTAS Announces New Antibody Optimisation Agreement with Teva Pharmaceuticals
Product News

IONTAS Announces New Antibody Optimisation Agreement with Teva Pharmaceuticals


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "IONTAS Announces New Antibody Optimisation Agreement with Teva Pharmaceuticals"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

IONTAS Limited (IONTAS), a leader in antibody discovery and optimisation of human monoclonal antibody libraries, announced an agreement with Teva Pharmaceuticals (Teva) to apply its technologies and know-how to the optimisation of human antibodies for use as biotherapeutics.

Under the terms of the agreement, IONTAS will initially apply its proprietary technologies to provide Teva with a panel of optimised antibodies against a defined target. Teva will have the option to enter into further optimisation programmes in the future. The agreement also includes options for the screening of biophysical properties suitable for developable antibodies.

Dr John McCafferty, Founder and Chief Executive Officer of IONTAS, commented: “Our experience in both antibody discovery and optimisation enables us to generate antibodies that meet the stringent characteristics required by our Partners and the selection of IONTAS by Teva is a validation of this know-how and expertise. With our ability to focus on function, affinity, specificity and developability we can generate lead antibodies with lower risk of Chemistry, Manufacturing and Controls issues.”
Advertisement